Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Nevirapine concentrations in newborns receiving an extended prophylactic regimen.

Mirochnick M, Nielsen-Saines K, Pilotto JH, Pinto J, Jiménez E, Veloso VG, Parsons T, Watts DH, Moye J, Mofenson LM, Camarca M, Bryson Y; NICHD/HPTN 040/PACTG 1043 Protocol Team.

J Acquir Immune Defic Syndr. 2008 Mar 1;47(3):334-7.

PMID:
18398973
2.

Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results.

Chadwick EG, Capparelli EV, Yogev R, Pinto JA, Robbins B, Rodman JH, Chen J, Palumbo P, Serchuck L, Smith E, Hughes M; P1030 team.

AIDS. 2008 Jan 11;22(2):249-55.

PMID:
18097227
3.

Population pharmacokinetics of lamivudine in human immunodeficiency virus-exposed and -infected infants.

Tremoulet AH, Capparelli EV, Patel P, Acosta EP, Luzuriaga K, Bryson Y, Wara D, Zorrilla C, Holland D, Mirochnick M; Pediatric AIDS Clinical Trials Group.

Antimicrob Agents Chemother. 2007 Dec;51(12):4297-302. Epub 2007 Sep 24.

4.

Age-related effects on nelfinavir and M8 pharmacokinetics: a population study with 182 children.

Hirt D, Urien S, Jullien V, Firtion G, Rey E, Pons G, Blanche S, Treluyer JM.

Antimicrob Agents Chemother. 2006 Mar;50(3):910-6.

5.

Safety and pharmacokinetics of nelfinavir coadministered with zidovudine and lamivudine in infants during the first 6 weeks of life.

Mirochnick M, Stek A, Acevedo M, Keller M, Holland D, Capparelli E, Connor J, Huang S, Hughes M, Watts H, Mofenson L, Bryson Y.

J Acquir Immune Defic Syndr. 2005 Jun 1;39(2):189-94.

PMID:
15905735
6.

Bayesian parameter estimates of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1.

Payen S, Faye A, Compagnucci A, Giaquinto C, Gibbs D, Gomeni R, Bressolle F, Jacqz-Aigrain E.

Antimicrob Agents Chemother. 2005 Feb;49(2):525-35.

7.

Pharmacokinetics of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1.

Litalien C, Faye A, Compagnucci A, Giaquinto C, Harper L, Gibb DM, Jacqz-Aigrain E; Paediatric European Network for Treatment of AIDS Executive Committee.

Pediatr Infect Dis J. 2003 Jan;22(1):48-55.

PMID:
12544409
8.

Dose-escalating study of the safety and pharmacokinetics of nelfinavir in HIV-exposed neonates.

Rongkavilit C, van Heeswijk RP, Limpongsanurak S, Thaithumyanon P, Boonrod C, Hassink EA, Srigritsanapol A, Chuenyam T, Ubolyam S, Hoetelmans RM, Ruxrungtham K, Lange JM, Cooper DA, Phanuphak P.

J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):455-63.

PMID:
11981361
9.

Pharmacokinetics of nelfinavir in human immunodeficiency virus-infected infants.

Capparelli EV, Sullivan JL, Mofenson L, Smith E, Graham B, Britto P, Becker MI, Holland D, Connor JD, Luzuriaga K; Pediatric ACTG 356 Investigators.

Pediatr Infect Dis J. 2001 Aug;20(8):746-51.

PMID:
11734735
10.

Pharmacokinetics of zidovudine and lamivudine in neonates following coadministration of oral doses every 12 hours.

Moodley D, Pillay K, Naidoo K, Moodley J, Johnson MA, Moore KH, Mudd PN Jr, Pakes GE.

J Clin Pharmacol. 2001 Jul;41(7):732-41.

PMID:
11452705
11.

Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate.

Krogstad P, Wiznia A, Luzuriaga K, Dankner W, Nielsen K, Gersten M, Kerr B, Hendricks A, Boczany B, Rosenberg M, Jung D, Spector SA, Bryson Y.

Clin Infect Dis. 1999 May;28(5):1109-18.

PMID:
10452644
12.

Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction.

Heald AE, Hsyu PH, Yuen GJ, Robinson P, Mydlow P, Bartlett JA.

Antimicrob Agents Chemother. 1996 Jun;40(6):1514-9.

13.

(-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro.

Coates JA, Cammack N, Jenkinson HJ, Jowett AJ, Jowett MI, Pearson BA, Penn CR, Rouse PL, Viner KC, Cameron JM.

Antimicrob Agents Chemother. 1992 Apr;36(4):733-9.

Supplemental Content

Support Center